Bausch Health Cos (NYSE:BHC) Stock Rating Upgraded by Wall Street Zen

Posted by Geri Gentry on Aug 3rd, 2026

Bausch Health Cos (NYSE:BHC – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued on Saturday.

Other research analysts have also recently issued reports about the company. Royal Bank Of Canada reduced their price objective on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a research report on Monday, April 27th. Zacks Research lowered Bausch Health Cos from a “hold” rating to a “strong sell” rating in a research report on Friday, July 24th. Jefferies Financial Group upgraded Bausch Health Cos to a “hold” rating in a research note on Wednesday, July 22nd. Finally, Weiss Ratings downgraded Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th. Five analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $8.00.

View Our Latest Analysis on BHC

Bausch Health Cos Trading Up 0.1%

Shares of NYSE:BHC opened at $6.90 on Friday. The firm has a market cap of $2.58 billion, a price-to-earnings ratio of -2.33 and a beta of 0.42. Bausch Health Cos has a 12 month low of $4.33 and a 12 month high of $8.69. The company’s fifty day simple moving average is $4.99 and its 200 day simple moving average is $5.46. The company has a quick ratio of 1.08, a current ratio of 1.44 and a debt-to-equity ratio of 54.68.

Bausch Health Cos (NYSE:BHC – Get Free Report) last announced its earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.30. The firm had revenue of $2.83 billion during the quarter, compared to analyst estimates of $2.59 billion. Bausch Health Cos had a negative net margin of 10.12% and a negative return on equity of 561.95%. As a group, research analysts forecast that Bausch Health Cos will post 4.05 EPS for the current fiscal year.

Insider Buying and Selling at Bausch Health Cos

In related news, Director Frank D. Lee sold 24,456 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total transaction of $132,796.08. Following the transaction, the director directly owned 49,339 shares in the company, valued at approximately $267,910.77. The trade was a 33.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 20.67% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Caption Management LLC increased its stake in shares of Bausch Health Cos by 101.1% during the 4th quarter. Caption Management LLC now owns 4,464 shares of the company’s stock worth $31,000 after purchasing an additional 405,789 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Bausch Health Cos by 12,589.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock valued at $34,000 after purchasing an additional 4,910 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in Bausch Health Cos by 6,661.2% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after purchasing an additional 5,329 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Bausch Health Cos by 65.9% during the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after purchasing an additional 3,106 shares during the period. Finally, Camelot Portfolios LLC bought a new position in Bausch Health Cos during the fourth quarter worth about $59,000. Institutional investors own 78.65% of the company’s stock.

About Bausch Health Cos

(Get Free Report)

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.